In addition, TIAM1-overexpressed multidrug-resistant lymphoma cell lines targeted with dual TIAM1-RAC1 and NOTCH pathway inhibitors improved sensitivity to adriamycin [87]. The gene discussed is TIAM1; the disease is lymphoma.